When immune checkpoint inhibitors are used in patients with high CXCL10 expression, they block inhibitory receptors on the surface of T cells, which triggers higher levels of immune cells to recognize and kill tumor cells, resulting in higher response rates and improved efficacy of cancer treatment. This evidence concerns the gene CXCL10 and cancer.